Newsletters

[Nature Chemical Biology] Researchers identified PRC2 inhibitors as potent inducers of β cell-enriched gene expression in α cells, acting through modulation of the AR–ETV1 complex.

[Diabetes] Investigators showed that adipose tissue palmitoylation cycling helps preserve pancreatic β-cell function and insulin secretion despite sustained insulin resistance.

[Signal Transduction and Targeted Therapy] The authors investigated the role of methyltransferase 3-mediated RNA methylation in pancreatic acinar cell carcinoma development and progression.

[Cancer Research] Scientists demonstrated that the αv integrin and neuropilin-1 dual targeting iRGD peptide reverses some of these tumor microenvironment features by inhibiting transforming growth factor β (TGFβ) activation in the tumor, a process mediated by the αvβ5 integrin.

[Journal of Advanced Research] Researchers identified a small molecule as a therapeutic agent for pancreatic cancer through dual mechanisms, specifically Discoidin domain receptor 1 (DDR1) inhibition and methuosis induction.

[Cancer Immunology Research] Investigators showed that targeting C-C motif chemokine receptor 1 (CCR1) remodels the pancreatic tumor microenvironment, reducing myeloid-driven immunosuppression and enhancing CD8+ T-cell activity and immunotherapy response.

[Genes & Development] Scientists highlight lysosomal metabolism as a key survival mechanism in pancreatic cancer, linking nutrient recycling, tumor–host crosstalk, and immune evasion to potential therapeutic vulnerabilities.

[University of Oklahoma] A University of Oklahoma researcher has received a five-year, $2 million grant from the National Cancer Institute to investigate how pancreatic cancer uses cholesterol to survive chemotherapy.

[UCLA Health] Dr. Cristina Puig-Saus, an associate professor of microbiology, immunology and molecular genetics and surgical oncology at the David Geffen School of Medicine at UCLA and her research team have received grant from the National Cancer Institute to develop drug-based strategies that could enhance cancer immunotherapy for patients with melanoma and potentially other types of cancer.

[Science Advances] Researchers profiled longitudinal biopsies from patients with melanoma treated in the Phase Ib NIBIT-M4 epi-immunotherapy trial using single-cell multiome and spatial transcriptomics. Responders displayed enrichment of antigen presentation/interferon program and coordinated T and B cell expansion, whereas nonresponders retained stable neural crest–like clusters.

[Nature Medicine] Scientists presented the complete results of a Phase I trial investigating the safety and efficacy of autologous B7-H3-targeting chimeric antigen receptor T cell therapy for the treatment of recurrent glioblastoma.

[Cancer Research] Investigators identified innate immune remodeling as a key contributor to targeted therapy durability and identify NK cell recruitment, promoted in part by regression-associated macrophages, as a therapeutically actionable node for extending durability of response across oncogene-driven cancers.